← Back to Search

Topoisomerase I inhibitors

LMP744 for Lymphoma

Phase 1
Waitlist Available
Led By Alice P Chen, M.D.
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have histologically documented metastatic solid tumors which have progressed after one line of therapy, or lymphoma which has progressed after initial therapy and without potentially curative options, or patient refuses potentially curative therapy.
Patients must have measurable or evaluable disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cycle 1
Awards & highlights

Study Summary

This trial is testing the safety of a new drug, LMP744, which damages DNA and causes cell death, in order to see if it can treat certain kinds of cancer. Researchers will be testing the safety of the drug and what dose of the drug can be safely given to humans.

Eligible Conditions
  • Lymphoma
  • Solid Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have advanced cancer that has spread to other parts of your body and has not responded to initial treatment.
Select...
You have a condition that can be measured or evaluated by the doctors.
Select...
You can have received treatment with topoisomerase I inhibitors in the past.
Select...
You can participate in this therapy if you are not currently taking denosumab or bisphosphonates for any type of cancer, or if you are not undergoing hormone therapy for prostate cancer.
Select...
You are willing to give blood and tumor samples for research if you are in the later part of the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cycle 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and cycle 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To establish the safety, tolerability and the maximum tolerated dose (MTD) of LMP744 (NSC 706744)
Secondary outcome measures
Pyruvate Kinase

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
LMP744 will be administered IV over 1 hour on days 1-5 of each 28-day cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LMP744
2017
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,658 Previous Clinical Trials
40,924,605 Total Patients Enrolled
1,381 Trials studying Lymphoma
382,365 Patients Enrolled for Lymphoma
Alice P Chen, M.D.Principal InvestigatorNational Cancer Institute (NCI)
16 Previous Clinical Trials
3,632 Total Patients Enrolled
5 Trials studying Lymphoma
3,186 Patients Enrolled for Lymphoma
Geraldine H O'Sullivan Coyne, M.D.Principal InvestigatorNational Cancer Institute (NCI)
2 Previous Clinical Trials
67 Total Patients Enrolled

Media Library

LMP744 (Topoisomerase I inhibitors) Clinical Trial Eligibility Overview. Trial Name: NCT03030417 — Phase 1
Lymphoma Research Study Groups: Treatment Arm
Lymphoma Clinical Trial 2023: LMP744 Highlights & Side Effects. Trial Name: NCT03030417 — Phase 1
LMP744 (Topoisomerase I inhibitors) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03030417 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the odds of experiencing negative side effects from LMP744?

"LMP744's safety is estimated to be a 1 because it is a Phase 1 trial, meaning that there is only initial data supporting safety and efficacy."

Answered by AI
Recent research and studies
Cancer ResearchJournal
Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
Antony, Smitha, Keli K. Agama, Ze-Hong Miao, Kazutaka Takagi, Mollie H. Wright, Ana I. Robles, Lyuba Varticovski, et al.. 2007. “Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance”. Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/0008-5472.can-07-0938.
Current Topics in Medicinal ChemistryJournal
Non-camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy
Ling-hua, Meng, Liao Zhi-yong, and Yves Pommier. 2003. “Non-camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy”. Current Topics in Medicinal Chemistry. Bentham Science Publishers Ltd.. doi:10.2174/1568026033452546.
Molecular PharmacologyJournal
Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison
Antony, Smitha, Glenda Kohlhagen, Keli Agama, Muthusamy Jayaraman, Shousong Cao, Farukh A. Durrani, Youcef M. Rustum, Mark Cushman, and Yves Pommier. 2004. “Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison”. Molecular Pharmacology. American Society for Pharmacology & Experimental Therapeutics (ASPET). doi:10.1124/mol.104.003889.
clinicaltrials.govStudy
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
2017. "Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03030417.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top